Our top pick for
Krystal Biotech, Inc is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 51 staff and has a market cap (total outstanding shares value) of USD$960.6 million.
|52-week range||USD$36.37 - USD$66.85|
|50-day moving average||USD$45.9903|
|200-day moving average||USD$46.111|
|Wall St. target price||USD$81.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.199|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-5.83%|
|Return on equity TTM||-8.58%|
|Market capitalisation||USD$960.6 million|
TTM: trailing 12 months
There are currently 1.8 million Krystal Biotech shares held short by investors – that's known as Krystal Biotech's "short interest". This figure is 8.5% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Krystal Biotech shares can be evaluated.
Krystal Biotech's "short interest ratio" (SIR) is the quantity of Krystal Biotech shares currently shorted divided by the average quantity of Krystal Biotech shares traded daily (recently around 130102.53623188). Krystal Biotech's SIR currently stands at 13.8. In other words for every 100,000 Krystal Biotech shares traded daily on the market, roughly 13800 shares are currently held short.
However Krystal Biotech's short interest can also be evaluated against the total number of Krystal Biotech shares, or, against the total number of tradable Krystal Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Krystal Biotech's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Krystal Biotech shares in existence, roughly 90 shares are currently held short) or 0.1205% of the tradable shares (for every 100,000 tradable Krystal Biotech shares, roughly 121 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Krystal Biotech.
Find out more about how you can short Krystal Biotech stock.
We're not expecting Krystal Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $36.37 up to $66.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 1.0847. This would suggest that Krystal Biotech's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.